Literature DB >> 29061818

The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.

Leonie Müller1,2, Arlo Radtke1, Jennifer Decker1,2, Michael Koch2, Gazanfer Belge3.   

Abstract

BACKGROUND: Studies have revealed that cancer might be treated with cannabinoids since they can influence cancer cell survival. These findings suggest an alternative treatment option to chemo- and radiotherapy, that are associated with numerous adverse side-effects for the patients.
MATERIALS AND METHODS: Viability staining was conducted on lung cancer, testicular cancer and neuroblastoma cells treated with different concentrations of the synthetic cannabinoid WIN 55,212-2 and the percentage of dead cells was compared. Activity of apoptosis-related enzymes was investigated by the presence of DNA ladder in gel electrophoresis.
RESULTS: Treatment with different WIN 55,212-2 concentrations led to a significant dose-dependent reduction of cell viability. A DNA ladder was observed after WIN 55,212-2 treatment of testicular cancer and lung cancer cells.
CONCLUSION: The application of WIN 55,212-2 was found to trigger cell death in the investigated cell lines. The decline in lung cancer and testicular cancer cell viability seems to have been caused by apoptosis. These findings may contribute to development of alternative cancer therapy strategies. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  WIN 55,212-2; apoptosis; lung cancer; neuroblastoma; testicular cancer

Mesh:

Substances:

Year:  2017        PMID: 29061818     DOI: 10.21873/anticanres.12086

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  The Synthetic Cannabinoid WIN55,212-2 Can Disrupt the Golgi Apparatus Independent of Cannabinoid Receptor-1.

Authors:  Joshua Lott; Emily M Jutkiewicz; Manojkumar A Puthenveedu
Journal:  Mol Pharmacol       Date:  2022-03-02       Impact factor: 4.054

3.  Cannabinoid WIN 55,212-2 Inhibits Human Glioma Cell Growth by Triggering ROS-Mediated Signal Pathways.

Authors:  Kun Wang; Qian Wang; Qinghao Li; Zhaoqiang Zhang; Jing Gao; Cundong Fan; Baoliang Sun; Qingbin Ni
Journal:  Biomed Res Int       Date:  2021-04-22       Impact factor: 3.411

Review 4.  Cannabinoid Receptors Signaling in the Development, Epigenetics, and Tumours of Male Germ Cells.

Authors:  Marco Barchi; Elisa Innocenzi; Teresa Giannattasio; Susanna Dolci; Pellegrino Rossi; Paola Grimaldi
Journal:  Int J Mol Sci       Date:  2019-12-18       Impact factor: 5.923

Review 5.  Cannabinoids and Prostate Cancer: A Systematic Review of Animal Studies.

Authors:  Kanika Singh; Negar Jamshidi; Roby Zomer; Terrence J Piva; Nitin Mantri
Journal:  Int J Mol Sci       Date:  2020-08-29       Impact factor: 5.923

Review 6.  Cannabinoids in the landscape of cancer.

Authors:  Nagina Mangal; Simon Erridge; Nagy Habib; Anguraj Sadanandam; Vikash Reebye; Mikael Hans Sodergren
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-14       Impact factor: 4.553

Review 7.  Endocannabinoid System and Tumour Microenvironment: New Intertwined Connections for Anticancer Approaches.

Authors:  Marta Iozzo; Giovanna Sgrignani; Giuseppina Comito; Paola Chiarugi; Elisa Giannoni
Journal:  Cells       Date:  2021-12-02       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.